Drug Resistance in Leishmaniasis
University of London · University of Dundee · +4 more institutions
Abstract
Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and…
Citation impact
- FWCI
- 67.85
- Percentile
- 100%
- References
- 230
Authors
3- SLSimon L. CroftCorresponding
University of London, University of Dundee, London School of Hygiene & Tropical Medicine, Institute of Medical Sciences, Wellcome Trust, Banaras Hindu University
- SSShyam Sundar
University of London, University of Dundee, London School of Hygiene & Tropical Medicine, Institute of Medical Sciences, Wellcome Trust, Banaras Hindu University
- AHAlan H. Fairlamb
University of London, University of Dundee, London School of Hygiene & Tropical Medicine, Institute of Medical Sciences, Wellcome Trust, Banaras Hindu University
Topics & keywords
- Miltefosine
- Paromomycin
- Visceral leishmaniasis
- Leishmaniasis
- Drug resistance
- Drug
- Medicine
- Leishmania
- Good health and well-being